Follow The Filings

XENE Xenon Pharmaceuticals Inc.

Health Care, filed as XENON PHARMACEUTICALS INC (COM), Equity As of 2026 Q2 among managers we track Quote on Google Finance, opens in a new tab

  • 4 Owners
  • Max 2.9%
  • $34M

Who owns this now

Largest portfolio weights among holders, up to 2.9% (Nathan Fischel, Dafna Capital Management). Not free-float ownership.

  1. Nathan Fischel 2.9%
  2. Palo Alto Investors 0.43%
  3. Stanley Druckenmiller 0.28%

Who owns XENE

Sorted by value, long equity only, as of 2026 Q2.

History
Nathan Fischel, Dafna Capital Management 2.9% Hold 250,772 $15M History
Stanley Druckenmiller, Duquesne Family Office 0.28% Hold 238,600 $14M History
Palo Alto Investors 0.43% Hold 51,345 $3.1M History
Ron Baron, Bamco Inc. (Baron Capital) <0.01% Hold 25,000 $1.5M History

4 current, options excluded

Weight bar: held both quarters added sold at this quarter’s reported price

Insider trades

Open-market buys and sales by XENE's executives, directors and 10% owners in the last 12 months, from their Form 4s

All XENE insider trades
  • $1.7M bought by 2 insiders
  • $641K sold by 1 insider outside a trading plan
  • $19.6M sold by 2 insiders under 10b5-1 plans
  1. Thomas Patrick Kelly CFO
    Buy
    $560K 15,000 shares at $37.32 New stake
    Traded Sep 30 Filed Oct 1
    ↗
  2. Ian Mortimer CEO
    Buy
    $1.1M 30,000 shares at $37.38 +151% to stake
    Traded Sep 30 Filed Oct 1
    ↗
  3. Christopher John Kenney Chief Medical Officer
    Planned sale
    $426K 7,068 shares at $60.25 100% of stake
    Traded Aug 28 Filed Aug 31
    ↗
  4. Steven Gannon Director
    Sale
    $641K 10,000 shares at $64.06 84% of stake
    Traded Aug 11 Filed Aug 13
    ↗
  5. Ian Mortimer CEO
    Planned sale
    $16.3M 270,000 shares at $60.33 98% of stake
    Traded Mar 9 Filed Mar 11
    ↗
  6. Ian Mortimer CEO
    Planned sale
    $1.8M 40,000 shares at $44.43 87% of stake
    Traded Jan 2 Filed Jan 2
    ↗
  7. Ian Mortimer CEO
    Planned sale
    $1.1M 25,205 shares at $45.33 81% of stake
    Traded Dec 5–8 Filed Dec 9, 2025
    ↗
  8. Ian Mortimer CEO
    Planned sale
    $4,366 97 shares at $45.01 0.3% of stake
    Traded Nov 28, 2025 Filed Dec 3, 2025
    ↗

Also filed in the last 12 months, not counted as buying or selling: 21 option exercises, 8 sales to cover taxes, and 2 share withholdings for taxes.

SEC filings

Recent issuer filings from EDGAR, 18 shown.

Filed Form Detail Links
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
SCHEDULE 13G/A — Filing Doc
8-K 2.02,7.01,9.01 Filing Doc
10-Q Filing Doc
DEF 14A Filing Doc
DEFA14A Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 8.01,9.01 Filing Doc
424B5 Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B5 Filing Doc

Source: SEC EDGAR submissions, updated 5 days ago. All on EDGAR

Financials

US-GAAP annual figures by fiscal year, as tagged in Form 10-K. Each value links to its SEC filing.

Income statement

Metric FY2023 FY2024 FY2025
Net income -$182.39M -$234.33M -$345.91M

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $644.96M $635.26M $560.65M
Total non-current assets * $319.84M $162.88M $72.51M
Total assets $964.8M $798.14M $633.16M
Total current liabilities $27.27M $35.59M $41.79M
Total non-current liabilities * $9.6M $7.65M $9.61M
Total equity $927.92M $754.9M $581.76M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$145.33M -$181.39M -$279.12M
Cash from investing -$117.17M $165M $218M
Cash from financing $353.52M $12.13M $117.11M
Net change in cash $91.4M -$5.93M $56.45M

Source: SEC companyfacts (US-GAAP 10-K). A * marks a computed figure, not a single XBRL tag. Fiscal years are as the issuer labels them. Follow The Filings does not adjust or audit these figures.

Ownership over time

13Fs that reported it each quarter. Click a bar for that quarter’s holders.